Dr Schär opens an AI-based research centre in Trieste

Dr Schär opens an AI-based research centre in Trieste
- Information
Dr Schär has just inaugurated its Trieste R&D Centre, renewing the existing complex with a high-tech pilot plant.
With an investment of approximately 1,2 million euros, the facility marks an important step in the innovation journey of specialised nutrition. It is not merely a new production space, but an environment designed to bring research even closer to its practical application.
Accelerating development with high technologies
“Here,” explains the South Tyrolean company, “today present in 11 countries with 18 offices in the Americas and Europe – we can accelerate product development through the application of artificial intelligence, making the transition from the experimental phase to the industrial process smoother and more direct.”
Fully wired and digitalised, the plant enables advanced operations: collecting, reading and interpreting the data arriving from the machinery becomes an integral part of the development process. This means that formulations can be continuously improved, validation times reduced and higher quality standards guaranteed.
“In this context, technological innovation and a strong focus on sustainability in food production go hand in hand. The aim is not only to make the supply chain more efficient, but also to contribute to a more responsible model capable of generating value over time.”

Virna Cerne, senior director of global research & development of Dr Schär R&D Centre
Trieste, the capital of Dr Schär research since 2003
The new facility is part of an research ecosystem that has been active in Trieste – a city traditionally devoted to science – for over twenty years. Since 2003, the local research centre has brought together a group of 35 researchers, with expertise ranging from food chemistry to biotechnology, as well as the study of raw materials and agronomic projects.
“This integrated approach enables us to make full use of our team’s cross-functional expertise, work in increasingly broad and complex application areas and progressively expand our scope of action,” comments Virna Cerne, senior director of global research & development of Dr Schär R&D Centre. “In this way, we can put our scientific and technological knowledge at the service of diverse nutritional needs, developing solutions that are increasingly targeted, effective and responsive to people’s concrete needs.”
28 million invested in 2026
Over the years, the company, a leader in gluten-free products and with a consolidated turnover of 632 million euros (+1,3% compared with 2024) compared with 561 million in 2023, has gone beyond gluten-free, progressively broadening its scope of action and developing solutions for complex needs, such as kidney failure or clinical ketogenic diets (the regimen is very low in carbohydrates, high in fat and provides a moderate intake of protein). This journey has created an established body of expertise and knowledge, evidenced by 15 patent families (43 individual patents).
In 2025, Dr Schär invested a total of 8,8 million euros in improving production and logistics efficiency. The plan for 2026 provides for the allocation of 28 million euros, concentrated mainly in Italy, Spain and Germany.
This article was translated from the original version in Italian with the assistance of artificial intelligence. In case of discrepancies, please refer to the original version in Italian.